Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line pembrolizumab plus chemotherapy with or without olaparib maintenance in advanced BRCA-nonmutated epithelial ovarian cancer
MOH_2018-12-17_004823Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab, olaparib, carboplatin and paclitaxel in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (3 arms), sponsored by Merck & Co. Started Oct 2018; status: active, not recruiting.
02
Drugs
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on MOH_2018-12-17_004823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-17_004823.